O.25Phase 1 clinical trial of losmapimod in FSHD: safety, tolerability and target engagement

Autor:	Sander Brooks, Geert Jan Groeneveld, Michelle Mellion, E. van Brummelen, Diego Cadavid, Lisa Pagan, U.A. Badrising, D. Thompson, Michelle Hage, L. Ronco, B.G.M. van Engelen
Rok vydání:	2019
Předmět:	Clinical trial medicine.medical_specialty Neurology Losmapimod business.industry Pediatrics Perinatology and Child Health Target engagement Physical therapy Medicine Safety tolerability Neurology (clinical) business Genetics (clinical)
Zdroj:	Neuromuscular Disorders. 29:S123
ISSN:	0960-8966
DOI:	10.1016/j.nmd.2019.06.308
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e406b32859d3b3eb4523fa8f59cf49b0 https://doi.org/10.1016/j.nmd.2019.06.308 Zobrazit plný text záznamu Full Text from ScienceDirect